We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $1.33B
1-Year Est. Return 864.5%
This Fund
S&P 500
This Quarter Est. Return
+54.02%
1 Year Est. Return
+864.5%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$762M
AUM Growth
+$305M
Cap. Flow
+$141M
Cap. Flow %
18.47%
Top 10 Hldgs %
63.32%
Holding
56
New
11
Increased
13
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$17.6M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$17.6M
3
RVMD icon
Revolution Medicines
RVMD
+$10.1M
4
VIR icon
Vir Biotechnology
VIR
+$9.89M
5
CORT icon
Corcept Therapeutics
CORT
+$9.35M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$11.7M
2
PEPG icon
PepGen
PEPG
+$568K
3
HELP
Cybin Inc
HELP
+$485K
4
NUVB.WS
Nuvation Bio Inc Warrants
NUVB.WS
+$88K
5
INO icon
Inovio Pharmaceuticals
INO
+$82.3K

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Consumer Staples 0.31%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
26
Crescent Biopharma
CBIO
$659M
$8.33M 1.09%
453,686
– –
SLNO
27
DELISTED
Soleno Therapeutics
SLNO
$6.7M 0.88%
+200,000
New +$7.84M
ALLO icon
28
Allogene Therapeutics
ALLO
$698M
$6.65M 0.87%
+2,725,000
New +$5.46M
CYTK icon
29
Cytokinetics
CYTK
$10B
$6.59M 0.87%
100,000
– –
CTNM
30
Contineum Therapeutics
CTNM
$641M
$6.45M 0.85%
494,000
– –
APGE icon
31
Apogee Therapeutics
APGE
$10.2B
$5.89M 0.77%
70,000
– –
RLMD icon
32
Relmada Therapeutics
RLMD
$462M
$5.86M 0.77%
+842,106
New +$3.98M
ZURA icon
33
Zura Bio
ZURA
$548M
$5.36M 0.7%
900,000
+850,000
+1,700% +$5.13M
MLTX icon
34
MoonLake Immunotherapeutics
MLTX
$1.28B
$5.13M 0.67%
275,000
– –
AVTX icon
35
Avalo Therapeutics
AVTX
$1.05B
$4.48M 0.59%
300,000
+25,000
+9% +$391K
INO icon
36
Inovio Pharmaceuticals
INO
$133M
$4.12M 0.54%
2,370,122
-50,000
-2% -$82.3K
GPCR icon
37
Structure Therapeutics
GPCR
$3.38B
$3.62M 0.47%
75,000
– –
SRPT icon
38
Sarepta Therapeutics
SRPT
$2.2B
$3.26M 0.43%
150,000
– –
HELP
39
Cybin Inc
HELP
$890M
$3.07M 0.4%
640,000
-75,000
-10% -$485K
OCUL icon
40
Ocular Therapeutix
OCUL
$2.28B
$2.96M 0.39%
+350,000
New +$3.34M
ANTX icon
41
AN2 Therapeutics
ANTX
$211M
$2.56M 0.34%
+749,035
New +$1.55M
CLNN icon
42
Clene
CLNN
$54.3M
$2.35M 0.31%
477,515
+277,778
+139% +$1.42M
ORIC icon
43
Oric Pharmaceuticals
ORIC
$1.37B
$2.24M 0.29%
+176,500
New +$2M
SLDB icon
44
Solid Biosciences
SLDB
$1.05B
$2.16M 0.28%
300,000
– –
IVVD icon
45
Invivyd
IVVD
$284M
$1.95M 0.26%
1,500,000
– –
LBRX
46
LB Pharmaceuticals
LBRX
$1.54B
$1.73M 0.23%
70,000
– –
KPTI icon
47
Karyopharm Therapeutics
KPTI
$42.4M
$1.69M 0.22%
302,536
+50,000
+20% +$381K
NRIX icon
48
Nurix Therapeutics
NRIX
$2.72B
$1.55M 0.2%
100,000
– –
UPB
49
Upstream Bio Inc
UPB
$366M
$1.35M 0.18%
150,000
– –
MIST icon
50
Milestone Pharmaceuticals
MIST
$144M
$793K 0.1%
666,666
– –
1
2
3

Similar funds

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.33B AUM 29.71% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.33B AUM 37.42% 1-Year Est. Return
MIC
Means Investment Company Bangor, Maine $1.32B AUM 24.33% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.32B AUM 30.92% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Boxer Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Boxer Capital Management held 56 positions worth $762M, up 67% from $457M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Boxer Capital Management deployed $141M of net new capital in Q1 2026, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Vaxcyte: 325,000 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Consumer Staples and Miscellaneous.

On the sell side, the largest reduction was PepGen, an estimated $568K trimmed.

  • Boxer Capital Management's largest Q1 2026 buy was Vaxcyte: 325,000 shares worth $18.9M.
  • Boxer Capital Management added most to Revolution Medicines in Q1 2026, an estimated $10.1M increase.
  • Boxer Capital Management's biggest Q1 2026 reduction was PepGen, cutting an estimated $568K.
  • Boxer Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $11.7M.
  • Boxer Capital Management's ten largest holdings make up 63% of its $762M portfolio in Q1 2026.
  • Boxer Capital Management opened 11 new positions and closed 2 in Q1 2026.
  • Boxer Capital Management's portfolio value rose 67% quarter-over-quarter to $762M.

Based on Boxer Capital Management's 13F filing for Q1 2026, filed 15 May 2026.